Enavatuzumab (PDL192) is a Humanized IgG1 Monoclonal Antibody Targeting TWEAK
Antibody-dependent cytotoxicity (ADCC) is a cell-mediated immune defense mechanism. The effector cells of the immune system actively cleave target cells, and their membrane surface antigens are bound by specific antibodies.…